

100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
% Protection
*
Control
Acamprosate
Baclofen
Acamprosate + Baclofen

Figure 1



A
Motor unit area
200
180
160
140
120
100
*
*
Control
GLU (60μM)
BCL (80nM)
ACP (0.32nM)
ACP+BCL
B
Motor unit number
200
180
160
140
120
100
*
*
Control
GLU (60μM)
BCL (80nM)
ACP (0.32nM)
ACP+BCL
C
Neurite length
200
180
160
140
120
100
*
*
Control
GLU (60μM)
BCL (80nM)
ACP (0.32nM)
ACP+BCL

Figure 2




Figure 3




Figure 4



A
Motor unit area
(% of control)
140
130
120
110
100
90
80
70
60
50
◊
*
RIL (5µM)
Control
GLU 60 µM
ACP (0.14nM)
BCL (36nM)
ACP (0.32nM)
BCL (80nM)
B
Neurite length
(%of control)
150
140
130
120
110
100
90
80
70
60
50
◊
*
RIL (5µM)
Control
GLU 60 µM
ACP (0.14nM)
BCL (36nM)
ACP (0.32nM)
BCL (80nM)

Figure 5



A
50
40
30
20
10
0
Improvement (%)
area
number
neurite length
BCL + ACP
Riluzole
BCL +ACP
+ Riluzole
B
200
150
100
50
0
Improvement (%)
area
number
neurite length
BCL + ACP
Riluzole
BCL +ACP
+ Riluzole

Figure 6